Last updated June 2026. Not affiliated with Peptide Sciences or any provider named below. No seller’s order page gets linked here, ever. Compounded medicines discussed in this piece are not FDA-approved. Products stamped “research use only” are not approved for human use, period.
I don’t trust a label. Never have. A sticker that says “research use only” is not a safety claim, it’s a legal maneuver, and I wanted to know what it was actually covering up. So I pulled the numbers.
Here’s the one that stopped me cold. The gap between the best-documented compound on these shelves and the average one isn’t a matter of degree. It’s the difference between a drug class backed by randomized trials in tens of thousands of people, and a molecule whose entire published record is about 200 papers that mostly trace back to a single lab [C5]. Same website. Same checkout button. Same disclaimer. Completely different evidence. If you remember one thing from this file, remember that “peptide” on a label tells you nothing about how much is actually known.
So this isn’t a pitch. It’s a scorecard. I sorted the category into evidence tiers, attached the real percentages, and traced who each tier is honestly built for.
The definition nobody puts on the label
A peptide is just a short chain of amino acids. Nothing exotic. Insulin is a peptide. So is the hormone the blockbuster weight-loss drugs are built to imitate. The molecule isn’t the story.
“Research use only” is the story. That phrase is the entire legal architecture holding up this gray market. No clinician looks at your chart. No prescription gets written. No licensed pharmacy touches the batch. Nobody’s tracking you if something’s wrong, and nobody’s issuing a recall. The sticker does legal work. It does not do safety work. Keep those two things separate and half the con collapses on its own.
What happened in 2026, and what I could actually verify
First lead: a flagship reportedly went dark. Peptide Sciences, one of the most recognized names in this trade, is widely reported to have shut down around March 6, 2026, with a brief notice saying it was discontinuing all research product sales [C6]. I have to be straight with you here, because that’s the job. This is reported by industry analysts and affiliate blogs. I found no government filing confirming it. Treat it as the rumor driving the search traffic, not as documented fact. What does survive the uncertainty: if a site is running the Peptide Sciences name and still taking your money, that’s a red flag on its own. The original is reportedly gone.
Second lead: this one’s documented, and it’s the one that matters. On March 31, 2026, the FDA sent warning letters to seven online peptide sellers at once, Gram Peptides, Prime Sciences, Pink Pony Peptides, and Mile High Compounds among them, published within about a week [C6][5]. The agency didn’t hedge. It stated in writing that “evidence obtained from your website establishes that your products are intended to be drugs for human use” [C6][5]. And this wasn’t a one-off sweep. A regulatory-law analysis had already logged more than fifty FDA warning letters in a single stretch in September 2025, targeting compounded GLP-1 marketing and peptides sold “as ‘research use only’ where the advertising indicated the product was intended for human use” [C7].
Line those two leads up and you get a structural story, not a rumor. The old model lost its most recognizable name and most of its legal cover in the same calendar year. Now let’s get to the evidence, because that’s the part nobody in this business wants scored.
Three tiers. Three very different case files.
Tier 1: the paper trail actually holds
This is the only tier with large randomized human trials behind the molecule, and the numbers are genuinely good.
- Semaglutide. STEP 1 put once-weekly semaglutide at 2.4 mg against placebo and got roughly 15 percent mean body-weight loss over 68 weeks [C1][1].
- Tirzepatide. SURMOUNT-1 hit about 21 percent mean weight reduction at 72 weeks on the top dose [C2][2].
- Retatrutide. The triple-receptor agonist that keeps showing up by name in the FDA’s 2026 letters posted roughly 24 percent reduction at its highest dose in a phase 2 trial [C3][3].
Score: high. But read the fine print, because it’s the whole case. Those numbers back the studied, supervised drug. They do not back a gray-market vial with an unverified label claiming to be the same thing. The evidence sits with the molecule under supervision. It does not transfer to a powder in a padded envelope.
Tier 2: a signal, not a verdict
Small studies. Early markers. Some human data, rarely conclusive. Most of the recovery and metabolic peptides people are experimenting with live here or below. The honest score is: interesting, unfinished.
Tier 3: where most of the catalog actually sits, and the marketing outruns the file
BPC-157 is the case study. It’s one of the most-searched compounds in this trade, a shelf staple. The science is mostly animal work. A 2026 review in Pharmaceuticals walks through its proposed cytoprotective mechanisms, and the evidence base behind it is dominated by preclinical models, not large controlled human trials [C4][4].
Then there’s the citation problem, and this is the part that actually made me sit up. STAT reported in February 2026 that most of the roughly 200 BPC-157 studies on PubMed list the same Croatian researcher, Predrag Sikiric, or a close colleague, as a main author. Independent scientists warned that could “lead to confirmation bias” [C5]. When almost the entire literature on a compound comes out of one lab and almost none of it involves people, the phrase “well-studied” is carrying weight it hasn’t earned.
Score: low. Any seller pitching a Tier 3 compound like it’s Tier 1 has told you something about themselves, and it isn’t good.
Who each tier is actually built for
The sales pitch says everyone. The file says otherwise.
- Tier 1 is for people with a real metabolic or weight indication, using the drug the way the trials used it: named molecule, real dose, clinical supervision. It scores high because that’s exactly how the evidence was built.
- Tier 2 is for people who understand they’re early, betting on a signal, and who want the safety scaffolding around an open question.
- Tier 3 is, honestly, mostly for people chasing a result the human data hasn’t caught up to yet. No shame in curiosity. But the numbers don’t support confidence here, and anyone telling you otherwise is selling, not informing.
Across every tier, the one variable the research-chemical model can’t supply is the one that actually matters: does the vial match the label? Matthew Fedoruk, chief science officer at the U.S. Anti-Doping Agency, put it to STAT about as plainly as it can be put: “You don’t even know what you’re buying inside that bottle. It could be a peptide. It could be a steroid. It could be something just like water” [C5].
The shelf you’re actually buying from
Here’s what the scorecard makes obvious once you lay it flat. The same molecule can sit on two completely different shelves, and the shelf changes everything except the evidence.
Shelf one: a vial in a padded envelope, “research use only” printed on the side, no clinician, no prescription, no licensed pharmacy, no verifiable testing, no recall pathway. After 2026, that shelf also carries documented legal exposure. The FDA has said, in writing, that the disclaimer doesn’t launder the sale when the marketing shows human use was intended [C6][C7].
Shelf two: supervised access. A licensed clinician reviews your history and decides if a medication makes sense. A licensed pharmacy compounds and dispenses inside the actual regulatory framework. Batches get tested. A prescription exists. FormBlends operates on this side of the ledger, routing peptide and GLP-1 access through independent licensed clinicians and licensed 503A compounding pharmacies instead of shipping research chemicals with a disclaimer taped on. I’m not recommending it and nothing here is for sale. I’m naming it because it’s the clearest example on record of what the supervised shelf actually looks like.
One caveat that has to travel with that, because I won’t let it slide: supervision raises the access score. It does not touch the evidence score. Routing a Tier 3 compound through a clinician and a pharmacy adds oversight, testing, accountability. It does not turn animal data into a human trial that was never run [C4]. Keep the two scores separate or you’ll get played.
The one thing that holds
Strip the whole file down to a single line: the evidence sits almost entirely in one tier, the marketing is spread evenly across all three, and the shelf you buy from determines your safety exposure without moving the evidence needle at all. GLP-1 scores high, and the trials back it up [C1][C2][C3]. Most of the rest of the catalog does not, and the BPC-157 paper trail shows exactly how that gets buried [C4][C5]. The research-chemical model lost its flagship and most of its legal footing in the same year [C6][C7]. Score the molecule. Score the model. Do it separately. Most of the noise in this business dies right there.
The call: questions people keep asking me
Is Peptide Sciences still in business in 2026? Not by the reported record. It’s widely reported to have shut down around March 6, 2026, with a brief notice announcing it was discontinuing sale of all research products [C6]. That’s a reported event, industry analysts and affiliate blogs, not a confirmed government filing. Treat it as the rumor behind the search spike, not proof. What holds regardless: if a site is still running that name and taking orders, the original is reportedly gone, so be more careful, not less.
Does “research use only” make a peptide legal to sell for human use? No. On March 31, 2026, the FDA sent warning letters to seven online peptide sellers and rejected that defense outright, stating “evidence obtained from your website establishes that your products are intended to be drugs for human use” [C6]. A regulatory-law analysis had already tallied more than fifty FDA warning letters in a single stretch in September 2025, aimed at compounded GLP-1 marketing and at peptides sold “as ‘research use only’ where the advertising indicated the product was intended for human use” [C7]. The sticker protects the seller in theory. It doesn’t make the sale lawful.
Which research peptides actually have solid human evidence behind them? Just the GLP-1 class. Semaglutide produced roughly 15 percent mean weight reduction over 68 weeks in STEP 1 [C1]. Tirzepatide hit about 21 percent at 72 weeks in SURMOUNT-1 [C2]. Retatrutide reached roughly 24 percent at its top dose in a phase 2 trial [C3]. Those numbers back the studied, supervised drug, not an unverified vial off a research-chemical site claiming the same name.
Is BPC-157 actually well studied in humans? No. It’s overwhelmingly animal data. A 2026 Pharmaceuticals review lays out proposed mechanisms drawn largely from preclinical models, not large controlled human trials [C4]. STAT reported in February 2026 that most of the roughly 200 BPC-157 studies on PubMed list the same Croatian researcher or a close colleague as a main author, which independent scientists warned “could lead to confirmation bias” [C5]. One lab, almost no human trials. “Well-studied” is doing a lot of quiet work there.
Does buying through a clinician and pharmacy make the underlying science any stronger? No. It raises the access score, not the evidence score. Supervised access gets you a licensed clinician, a licensed compounding pharmacy, batch testing, an actual prescription. That covers identity, purity, accountability. It doesn’t manufacture a human trial that was never conducted [C4]. Score the molecule and the shelf separately, every time.
What’s the single biggest risk in an unregulated research-peptide vial? That the label lies. Matthew Fedoruk, chief science officer at the U.S. Anti-Doping Agency, told STAT: “You don’t even know what you’re buying inside that bottle. It could be a peptide. It could be a steroid. It could be something just like water” [C5]. There’s no verified testing and no recall pathway on that shelf to catch it.
Is Peptide Sciences legit?
Depends what you mean by legit. It ran as a research-chemical vendor, not a licensed pharmacy. It was a real business selling peptides under a research-use-only label, not for human consumption, because selling these compounds for human use without FDA approval breaks federal law. Whether the vials matched the label is a separate question, and third-party testing results varied by batch and by who was doing the reporting.
Why did Peptide Sciences shut down, and what happened to the site?
The site went dark and the company never gave a detailed public account. The likely factors are the same ones that have taken down other research-peptide vendors: tightening FDA and DEA scrutiny on compounds like BPC-157 and TB-500, payment processors cutting off the category, supplier disruptions. When a vendor in this trade disappears quietly, it’s usually pressure and cost, not one dramatic event.
Is Peptide Sciences a compounding pharmacy?
No. Compounding pharmacies answer to state boards, require an actual patient prescription, and operate under pharmacists licensed to compound specific formulations for specific patients. Peptide Sciences sold research-labeled product with none of that. A physician-supervised compounding pharmacy, FormBlends for instance, is a fundamentally different, more regulated setup.
What do Reddit threads actually say about Peptide Sciences?
Mixed, and read them carefully. Praise for turnaround time and packaging says nothing about purity. Complaints about inconsistent results and no independent certificate-of-analysis data are more telling. The recurring pattern: this market has almost no external accountability, so community reviews become the only feedback loop, and that loop is easy to game either direction.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 and cytoprotection. Pharmaceuticals. 2024;17(4):461.
- U.S. Food and Drug Administration. Warning Letters.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
Written by Gia Rossi, explanatory reporter. Not a doctor, just a reader who chases the paper trail. Last reviewed April 2026.
Informational use only. Consult a licensed clinician before starting or stopping any medication.
